Department of Pharmacy Practice

College of Pharmacy

Larry H. Danziger

Larry Danziger Larry H. Danziger, PharmD, FIDSA
Co-Director, Section of Infectious Diseases Pharmacotherapy
Pharmacy Practice

Executive Director, Center for Advanced Research, Design and Exploration
Office of the Vice Chancellor for Research
Phone 312-996-0892 / 312-355-0090
Fax 312-413-1797
Office 105 COP, MC886 / B16 AOB
US Mail 833 South Wood Street, RM164, MC886, Chicago, IL 60612

Research Interests
Dr. Danziger's research interests include surgical infectious disease, the unusual properties of
antimicrobial agents and pharmacological aspects of the patients with infectious diseases.

1978 Doctor of Pharmacy degree, University of Cincinnati
1976 Bachelor of Science in Pharmacy, University of Illinois (Chicago)
1973 Bachelor of Arts in History, University of Illinois (Urbana)

Current UIC Appointments
2009 to Present Professor of Pharmacy in Medicine, Department of Infectious Diseases, College of Pharmacy
1995 to Present Professor with Tenure, Department of Pharmacy practice, College of Pharmacy
1995 to Present
CoDirector, Section of Infectious Diseases Pharmacotherapy

Representative Publications

  1. Suda K, Hicks, L, Roberts R, Hunkle R, Danziger L. A national evaluation of antibiotic expenditures by healthcare setting in the US, 2009. J Antimicrob Chemother Nov 2012, 1-4.
  2. Crawford T, Huesgen E, Danziger L, Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm. 2012 Jun 1;69(11):933-43. 
  3. Colvard M,  Naiman,  M,  Danziger L; Hanley L. Handheld Directed Energy Sensor for Environmental Monitoring and Clinician Safety. Aviation Space and Environmental Medicine. 2010;81:602-04.
  4. Wieczorkiewicz SM, Jourjy J, Danziger L,  An Update on the Pharmacoeconomics of Antifungal Pharmacotherapy. Current Fungal Infection Reports. 2009;3:103-110.
  5. DePestel DD, Benninger MS, Danziger L, LaPlante KL, May C, Luskin A, Pichichero M, Hadley JA. Cephalosporin use in treatment of patients with penicillin allergies. J Am Pharm Assoc (2003). 2008 Jul-Aug;48(4):530-40.
  6. Jain R, Schriever CA, Danziger LH, Cho SH, Rubinstein I. The IS6110 repetitive DNA element of Mycobacterium tuberculosis is not detected in exhaled breath condensate of patients with active pulmonary tuberculosis.Respiration. 2007;74(3):329-33.
  7. Itokazu GS, Schwartz DN, Garey KW, Rodvold KA, Danziger LH, Weinstein RA. Pharmacists' perceptions of the effectiveness of antimicrobial control programs. Am J Health Syst Pharm. 2006 Dec 15;63(24):2504-8.
  8. Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH. Rodvold KA. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis. 2006 Aug;55(4):303-9.
  9. Johnson MD, Kleinberg M, Danziger L, Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions. Expert Opin Pharmacother. 2005 Dec;6(15):2617-32.
  10. Suda K J, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolones. Pharm World Sci. 2005;27:81-82.
  11. Schriever CA, Fernandez C, Rodvold KA, Danziger LH. Daptomycin: A Novel Cyclic Lipopeptide Antimicrobial. Am J Health Syst Pharm. 2005 Jun 1;62(11):1145-58.
  12. Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):31-40.
  13. Lodise TP Jr, Lomaestro B, Rodvold K, Danziger L, Drusano G. Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation. Antimicrob Agents Chemother. 2004 Dec;48(12):4718-724.

Click here to view Dr. Danziger's abbreviated on-line CV. PDF logo

Return to faculty list